Saturday - May 10, 2025
Portage, Michigan, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) announced today that it has completed the acquisition of Vertos Medical Inc., a leader in interventional pain management solutions for chronic lower back pain caused by lumbar spinal stenosis.
“The acquisition of Vertos Medical enhances our unique, non-surgical solutions for interventionalists addressing chronic lower back pain, while broadening our presence in ambulatory surgery centers," said Andy Pierce, Group President, MedSurg and Neurotechnology, Stryker. “We look forward to enabling physicians with the minimally invasive mild® procedure so patients can reclaim their quality of life.”
The addition of Vertos Medical’s differentiated portfolio will strengthen Stryker’s impact in interventional solutions to address chronic pain.
About Stryker
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 150 million patients annually. More information is available at www.stryker.com.
Media contact
Beth Sizemore
Sr. Director, Strategic Communications
beth.sizemore@stryker.com
Last Trade: | US$380.92 |
Daily Change: | -1.54 -0.40 |
Daily Volume: | 729,029 |
Market Cap: | US$145.210B |
May 01, 2025 March 04, 2025 March 03, 2025 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load